Drugs / 5 Methoxy N,N Dimethyltryptamine
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07540494 | Apr → May 2026 overdue | — | GH Research Ireland Limited | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06511947 | Aug 2024 → Feb 2025 overdue | — | GH Research Ireland Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT05698095 | Dec 2022 → Sep 2023 | — | Usona Institute | Completed | No outcome recorded |
| Phase 1 | NCT05753956 | Dec 2022 → Nov 2023 | — | GH Research Ireland Limited | Completed | No outcome recorded |
| Phase 1 | NCT05163691 | Jun → Oct 2021 | — | GH Research Ireland Limited | Completed | No outcome recorded |
| Phase 1 | NCT04640831 | Mar → Oct 2019 | — | GH Research Ireland Limited | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT04698603 | Nov 2019 → Nov 2021 | major depressive disorder | GH Research Ireland Limited | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-19 | GH Research Ireland Limited | GH Research Ltd. Announces Completion of Phase 1 Clinical Study with GH001 (5-Methoxy-N,N-Dimethyltryptamine) in Healthy Volunteers and Updates on Further Progress ghres.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-Methoxy-N,N-Dimethyltryptamine | “A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression.” PMID 37409159 ↗ Jun 20236“5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects.” PMID 34912222 ↗ Nov 2021 |
| Known as | 5-methoxy-dimethyltryptamine | “The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive...” NCT04698603 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT05698095 ↗ |